Compare WLII & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WLII | NBP |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 225.5M |
| IPO Year | 2026 | N/A |
| Metric | WLII | NBP |
|---|---|---|
| Price | $10.28 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 98.9K | ★ 374.2K |
| Earning Date | N/A | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $1.46 |
| 52 Week High | $10.29 | $5.19 |
| Indicator | WLII | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 66.08 | 37.06 |
| Support Level | $10.23 | N/A |
| Resistance Level | $10.29 | $1.67 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 58.33 | 4.69 |
Willow Lane Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.